Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?

Thumbnail Image
1-s2.0-S0928098719301368-main.pdf(1.22 MB)
Published version
O'Driscoll, Caitríona M.
Bernkop-Schnürch, Andreas
Friedl, Julian D.
Préat, Véronique
Jannin, Vincent
Journal Title
Journal ISSN
Volume Title
Elsevier B.V.
Research Projects
Organizational Units
Journal Issue
Gene therapy with RNA and pDNA-based drugs is limited by poor enzymatic stability and poor cellular permeation. The delivery of nucleic acids, in particular by the oral route, remains a major hurdle. This review will focus on the barriers to the oral delivery of nucleic acids and the strategies, in particular formulation strategies, which have been developed to overcome these barriers. Due to their very low oral bioavailability, the most obvious and most investigated biomedical applications for their oral delivery are related to the local treatment of inflammatory bowel diseases and colorectal cancers. Preclinical data but not yet clinical studies support the potential use of the oral route for the local delivery of formulated nucleic acid-based drugs.
Nucleic acid , Oral delivery , RNA , pDNA , Nanoparticles , Lipid-based particles , Inflammatory bowel disease
O'Driscoll, C.M., Bernkop-Schnürch, A., Friedl, J.D., Préat, V. and Jannin, V., 2019. Oral delivery of non-viral nucleic acid-based therapeutics-do we have the guts for this?. European Journal of Pharmaceutical Sciences, 133, (14pp). DOI:10.1016/j.ejps.2019.03.027